M
Marc Pracht
Researcher at French Institute of Health and Medical Research
Publications - 88
Citations - 6852
Marc Pracht is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Hepatocellular carcinoma & Medicine. The author has an hindex of 25, co-authored 76 publications receiving 4603 citations.
Papers
More filters
Journal ArticleDOI
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix,Shukui Qin,Philippe Merle,Alessandro Granito,Yi Hsiang Huang,György Bodoky,Marc Pracht,Osamu Yokosuka,Olivier Rosmorduc,Valeriy Breder,René Gerolami,Gianluca Masi,Paul Ross,Tianqiang Song,Jean-Pierre Bronowicki,Isabelle Ollivier-Hourmand,Masatoshi Kudo,Ann-Lii Cheng,Josep M. Llovet,Josep M. Llovet,Josep M. Llovet,Richard S. Finn,Marie Aude Leberre,Annette Baumhauer,Gerold Meinhardt,Guohong Han +25 more
TL;DR: Regorafenib is the only systemic treatment shown to provide survival benefit in HCC patients progressing on sorafenIB treatment, and future trials should explore combinations of regorAFenib with other systemic agents and third-line treatments for patients who fail or who do not tolerate the sequence of sorafanib and regorafinib.
Journal ArticleDOI
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Andrew X. Zhu,Yoon-Koo Kang,Chia Jui Yen,Richard S. Finn,Peter R. Galle,Josep M. Llovet,Josep M. Llovet,Eric Assenat,Giovanni Brandi,Marc Pracht,Ho Yeong Lim,Kun-Ming Rau,Kenta Motomura,Izumi Ohno,Philippe Merle,Bruno Daniele,Dong Bok Shin,Guido Gerken,Christophe Borg,Jean-Baptiste Hiriart,Takuji Okusaka,Manabu Morimoto,Yanzhi Hsu,Paolo Abada,Masatoshi Kudo +24 more
TL;DR: Overall survival, progression-free survival, proportion of patients achieving an objective response, time to radiographic progression, safety, and time to deterioration in scores on the Functional Assessment of Cancer Therapy Hepatobiliary Symptom Index 8 (FHSI-8) were significantly improved in the ramucirumab group compared with the placebo group.
Journal ArticleDOI
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
Richard S. Finn,Masafumi Ikeda,Andrew X. Zhu,Max W. Sung,Ari David Baron,Masatoshi Kudo,Takuji Okusaka,Masahiro Kobayashi,Hiromitsu Kumada,Shuichi Kaneko,Marc Pracht,Konstantin Mamontov,Tim Meyer,Tomoki Kubota,Corina E. Dutcus,Kenichi Saito,Abby B. Siegel,Leonid Dubrovsky,Kalgi Mody,Josep M. Llovet,Josep M. Llovet +20 more
TL;DR: Lenvatinib plus pembrolizumab has promising antitumor activity in uHCC, and toxicities were manageable, with no unexpected safety signals.
Journal ArticleDOI
Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.
Julien Edeline,Eveline Boucher,Yan Rolland,Elodie Vauleon,Marc Pracht,Christophe Perrin,Catherine Le Roux,Jean-Luc Raoul +7 more
TL;DR: In this paper, a significant improvement in overall survival was demonstrated in patients with advanced hepatocellular carcinoma (HCC) who received Sorafenib (Sor) in the SHARP study, in contrast to a response rate (RR) of 2% assessed according to Response Evaluation Criteria in Solid Tumors (RECIST).
Journal ArticleDOI
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials
Harpreet Wasan,Peter Gibbs,Navesh K Sharma,Julien Taieb,Volker Heinemann,Jens Ricke,Marc Peeters,Michael Findlay,Andrew Weaver,Jamie Mills,Charles Wilson,Richard Adams,Anne Francis,Joanna Moschandreas,P S Virdee,Peter Dutton,Sharon Love,Val Gebski,Alastair Gray,Andrew Bateman,Claire Blesing,Ewan Brown,Ian Chau,Sebastian Cummins,David Cunningham,Stephen Falk,Maher Hadaki,Marcia Hall,Tamas Hickish,Joanne Hornbuckle,F. Lofts,Sarah Lowndes,Astrid Mayer,Matthew Metcalfe,Gary Middleton,Amir Montazeri,Rebecca Muirhead,Andreas Polychronis,Colin Purcell,Paul Ross,Ricky A. Sharma,Liz Sherwin,David J. Smith,Rubin Soomal,Daniel Swinson,Axel Walther,Harpreet Wasan,Greg Wilson,Pradip Amin,Bruna Angelelli,Jacques Balosso,Alex Beny,Daniel Bloomgarden,Evelyn Boucher,Michael P. Brown,Harald-Robert Bruch,James Bui,Matthew Burge,Giuseppe Cardaci,James Carlisle,Seungjean Chai,Yi-Jen Chen,Patrick Chevallier,Michael Chuong,Stephen Clarke,Andrew L. Coveler,Michael Craninx,Thierry Delanoit,Amélie Deleporte,Paul Eliadis,Francis Facchini,Tom Ferguson,Michel Ferrante,Gary Frenette,Jacob Frick,Vinod Ganju,Michael Garofalo,Karen Geboes,Gerald Gehbauer,Benjamin George,Ravit Geva,Michael Gordon,Kate Gregory,Seza Gulec,James Hannigan,Guy van Hazel,Norman Isaac Heching,Thomas Helmberger,Alain Hendlisz,Koen Hendrickx,Matthew Holtzman,Richard Isaacs,Christopher Jackson,Philip T. James,Adeel Kaiser,Chris Karapetis,Andreas Kaubisch,Yon-Dschun Ko,H. Kröning,Frank Lammert,Winston Liauw,Steven Limentani,Samy Louafi,Marc De Man,Jeffrey Margolis,Robert C.G. Martin,Andrea Martoni,Gavin Marx,Marco Matos,E Monsaert,Veerle Moons,Louise M. Nott,Arnd Nusch,Anne O'Donnell,Howard Ozer,Siddarth A Padia,Nick Pavlakis,David Perez,Stefan Pluntke,Marc Polus,Alex Powell,Marc Pracht,Timothy J. Price,David Ransom,Christine Rebischung,Karsten Ridwelski,Jorge Riera-Knorrenschild,Hanno Riess,William S. Rilling,Bridget A. Robinson,Javier Rodríguez,Federico Sanchez,Tilmann Sauerbruch,Michael Savin,Klemens Scheidhauer,Elyse Schneiderman,Grant Seeger,Eva Segelov,Einat Shaham Schmueli,Adi Shani,Jenny Shannon,Navesh K. Sharma,Stephen Shibata,Nimit Singhal,Denis Smith,Randall Smith,Salomon M. Stemmer,Oliver Stötzer,Andrew Strickland,Klaus Tatsch,Eric Terrebonne,Thomas Tichler,Ursula Vehling-Kaiser,Ruth Vera-Garcia,Thomas J Vogl,Euan Walpole,Eric Wang,Samuel Whiting,Ido Wolf,Steven Ades,Morteza Aghmesheh,Miklos Auber,Hubert Ayala,Patrick McKay Boland,Eveline Bouche,Charles Bowers,Christoph Bremer,M. Burge,Ana Ruíz Casado,Prasad Cooray,Martin R. Crain,Maike De Wit,Kyran Dowling,Aurelie Durand,Sandrine Faivre,Kynan Feeney,Thomas W. Ferguson,Aurelie Ferru,Maria Fragoso,Cristina Granetto,Pascal Hammel,Richard Issacs,Renuka Iyer,Yeul Hong Kim,Jin-Tung Liang,Lionel Lim,Jin Hwang Liu,Gianluca Masi,Stefania Mosconi,Gianmauro Numico,Lynn Ratner,Han Sae-Won,Madhu Sudan Singh,Patricia Stoltzfus,Iain Tan,Antonio Trogu,Craig Underhill,Mark Westcott +197 more
TL;DR: Data suggest selective internal radiotherapy (SIRT) in third-line or subsequent therapy for metastatic colorectal cancer has clinical benefit in patients with coloreCTal liver metastases with liver-dominant disease after chemotherapy.